Quanterix announced significant elevations in blood levels of amyloid beta (Abeta) 42 peptide, a hallmark of Alzheimer’s disease, were detected using the company’s the Single Molecule Array (SiMoA) technology in patients who experienced hypoxia following cardiac arrest.
A new organocatalyst developed at Oregon State University (OSU) could make new drug development around the world less costly, more efficient and more environmentally friendly, the developers say.
Using geriatric mice, researchers have shown that losartan, a commonly used blood pressure drug, not only improves regeneration of injured muscle but also protects against its wasting away from inactivity.
Disease-modifying drugs slow the progression of multiple sclerosis, and have been shown to reduce the frequency and severity of relapses. But a new study found low adherence to all DMDs, with less than half of patients continually adherent after two years.
A Goldman Sachs analyst said that investors are overlooking Johnson & Johnson's product pipeline, upgrading the stock to "Buy" while downgrading shares of Bristol-Myers Squibb Co. to "Neutral."
American Bioanalytical Inc. has received ISO 13485:2003 Certification, an internationally recognized quality standard designed to ensure that medical device manufacturers have required quality management systems.
Patheon announced the appointment of Michael E. Lytton as Patheon’s Executive Vice President, Corporate Development and Strategy and General Counsel, effective immediately.
G-Biosciences presents Sulfhydryl Coupling Resin which is designed for the simple and efficient coupling of peptides and proteins. Utilizing free sulfhydryl groups, a 6% agarose support is used in conjunction with covalent thioether bonds for stable coupling.
To meet the demands of the analytical world, Horizon Technology developed the Fast Flow Sediment Disk Holder. The Fast Flow Sediment Disk Holder allows laboratories to use an economical 47 mm SPE disk while still maintaining the use of a 100 mm prefilter.
Cytheris SA, the Centre Léon Bérard, and ImmunID Technologies SAS initiated a Phase 2a clinical trial that will evaluate multiple combinations of recombinant human interleukin-7 (CYT107) and XELODA in the treatment of metastatic breast cancer.
Genentech has submitted a New Drug Application for vemurafenib to the U.S. Food and Drug Administration for BRAF V600 mutation-positive metastatic melanoma, and that Roche submitted a Marketing Authorization Application to the European Medicines Agency for the same indication.
Boston Scientific Corp. said that a federal jury awarded it $19.5 million in a dispute with rival Johnson & Johnson over stents. A jury found that J&J's Cordis unit owed Boston Scientific for infringing its Jang patent.
SciClone Pharmaceuticals Inc. said that its first-quarter profit fell 8% on higher costs related to a government investigation alleging bribery to foreign officials in order to secure business overseas.
The Food and Drug Administration has approved the first flu shot injected with a tiny needle into skin cells rather than muscle. Sanofi Pasteur said that regulators approved the Fluzone Intradermal vaccine for adults 18 through 64 years old.
Teva Pharmaceutical Industries Ltd. said its profit rose 7 percent in the first quarter as its latest acquisitions boosted its sales overseas. The world's largest maker of generic drugs said its profit grew to $761 million.